semaglutide cardiovascular outcomes news Associated with in Type 2 Diabetes: A Systematic Review and Meta-Analysis Cardiovascular outcomes of semaglutide and

has received speaker fees from Takeda

Recent studies have reported cases of semaglutide-associated hyposalivation (a type of GLP-1 RA), where patients experienced minimal salivation and xerostomia, which dissipated as soon as they discontinued taking the GLP-1 RA ( Mawardi et al

and visceral hypersensitivity represents a final common pathway amplifying pain perception

Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), typically produces substantial weight reduction, but this progress naturally slows over time

Leptin ameliorates ischemic necrosis of the femoral head in rats with obesity induced by a high-fat diet